American International Group Inc. Has $670,000 Holdings in Luminex Co. (NASDAQ:LMNX)


Share on StockTwits

American International Group Inc. cut its position in shares of Luminex Co. (NASDAQ:LMNX) by 2.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,983 shares of the medical instruments supplier’s stock after selling 711 shares during the quarter. American International Group Inc. owned about 0.06% of Luminex worth $670,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Luminex by 5.9% during the fourth quarter. BlackRock Inc. now owns 8,163,784 shares of the medical instruments supplier’s stock worth $188,747,000 after buying an additional 451,620 shares during the period. Copeland Capital Management LLC grew its holdings in Luminex by 67.8% in the fourth quarter. Copeland Capital Management LLC now owns 1,385,225 shares of the medical instruments supplier’s stock worth $32,027,000 after purchasing an additional 559,909 shares during the period. Bank of New York Mellon Corp grew its holdings in Luminex by 4.6% in the fourth quarter. Bank of New York Mellon Corp now owns 593,193 shares of the medical instruments supplier’s stock worth $13,715,000 after purchasing an additional 26,163 shares during the period. Investment Management of Virginia LLC grew its holdings in Luminex by 21.4% in the fourth quarter. Investment Management of Virginia LLC now owns 543,311 shares of the medical instruments supplier’s stock worth $12,562,000 after purchasing an additional 95,700 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Luminex by 6.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 302,612 shares of the medical instruments supplier’s stock worth $7,944,000 after purchasing an additional 18,678 shares during the period. Institutional investors own 88.09% of the company’s stock.

In other Luminex news, CFO Harriss T. Currie sold 5,325 shares of the firm’s stock in a transaction on Monday, March 1st. The shares were sold at an average price of $32.35, for a total value of $172,263.75. 9.40% of the stock is currently owned by company insiders.

NASDAQ:LMNX opened at $31.74 on Thursday. The company has a current ratio of 6.45, a quick ratio of 5.01 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 81.39 and a beta of 0.61. The firm has a fifty day simple moving average of $31.74 and a two-hundred day simple moving average of $26.46. Luminex Co. has a 12 month low of $20.61 and a 12 month high of $41.69.

Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Sunday, February 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.12). Luminex had a return on equity of 3.75% and a net margin of 4.60%. The company had revenue of $111.39 million during the quarter, compared to analyst estimates of $104.57 million. During the same quarter in the previous year, the business posted $0.07 earnings per share. The company’s revenue for the quarter was up 23.1% compared to the same quarter last year. Equities analysts predict that Luminex Co. will post 0.44 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 15th. Shareholders of record on Thursday, March 25th will be paid a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date is Wednesday, March 24th. Luminex’s dividend payout ratio (DPR) is -190.48%.

Luminex Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer.

Featured Story: What is a dead cat bounce?

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.